| Developing Quantitative AI-histologic Signatures Associated with Prognosis and Treatment Benefit Across Cancer Types in the PLCO Trial |
Haochen Zhang |
Valar Labs |
PLCO |
Jul 14, 2026 |
PLCOI-2054 |
| Wildfire Smoke Exposure and Cancer-Related Outcomes in the NLST Cohort |
Shuguang Leng |
University of New Mexico |
NLST |
Jul 14, 2026 |
NLST-1518 |
| Vision–Language Learning for Generalizable Pulmonary Nodule Characterization in Low-Dose CT Screening |
Benjamin Wild |
Berlin Institute of Health at Charité |
NLST |
Jul 14, 2026 |
NLST-1521 |
| AEGIS-Lung — Deep-Learning Development and Internal Validation of an Integrated Lung-Cancer Risk Model in the NLST Cohort |
Aneel Paulus |
West Eastern Health |
NLST |
Jul 14, 2026 |
NLST-1522 |
| NeuroAI-Lung: Longitudinal Risk Stratification Using NLST Low-Dose CT Data |
Richard Tran |
Trove-AI |
NLST |
Jul 14, 2026 |
NLST-1519 |
| PLCO Germline Materials for Integrated Whole-Genome Discovery of Lung Cancer Susceptibility with the Sherlock-Lung Study |
Maria Teresa Landi |
National Cancer Institute, National Institutes of Health |
PLCO |
Jul 8, 2026 |
2026-0117 |
| ABO Blood Type and Secretor Status as Determinants of Oral Microbiome Composition and Cancer Risk: Evidence from the PLCO Cohort |
Emily Vogtmann |
National Cancer Institute |
PLCO |
Jun 18, 2026 |
PLCO-2058 |
| Longitudinal study of socioeconomic factors, stress-related biomarkers, and aggressive prostate cancer |
Kathryn Barry |
University of Maryland, Baltimore |
PLCO |
Jun 17, 2026 |
2026-0158 |
| Multi-population study of serum protein biomarkers and prostate cancer risk |
Sonja Berndt |
National Cancer Institute |
PLCO |
Jun 17, 2026 |
2026-0154 |
| Leveraging antibody responses against transposable elements as a novel immune therapy for ovarian cancer |
Rebecca Lynch |
The George Washington University School of Medicine and Health Sciences |
PLCO |
Jun 17, 2026 |
2026-0096 |
| Exosome-based microRNA Biomarkers for Non-invasive and Early Detection of Colorectal Cancer and Advanced Adenomas |
Ajay Goel |
City of Hope |
PLCO |
Jun 16, 2026 |
2025-0016 |
| Efficient Design and Analysis of Two-Phase Biomarker Studies |
Li Cheung |
National Cancer Institute |
PLCO |
Jun 8, 2026 |
PLCO-2053 |
| PLCO Digital Pathology Whole-Slide Images for Prostate, Lung, and Ovarian Cancer AI Modeling and Validation |
Yuming Jiang |
Wake Forest University Health Sciences |
PLCO |
Jun 8, 2026 |
PLCOI-2052 |
| Impact of deep learning lung cancer risk models on clinical decisions with blood-based diagnostics |
Michael Kammer |
Biodesix, inc |
NLST |
Jun 8, 2026 |
NLST-1515 |
| Oxford Pooling Project: Prostate (endogenous hormones and nutritional biomarkers):Updated (PLCO-350 Continued) |
Naomi Allen |
University of Oxford |
PLCO |
Jun 8, 2026 |
PLCO-2049 |
| External Validation and Site-Specific Retraining of CXR-Age for Cancer Outcome Prediction in an Academic Medical Center Cohort |
Judy Gichoya |
Emory University |
PLCO |
Jun 1, 2026 |
PLCOI-2050 |
| Designing a Targeted Lung Cancer (LC) Screening Trial in the U.S. Screening-Ineligible Population Using Synthetic Cohorts and Natural History Modelling |
Thomas Trikalinos |
Brown University |
PLCO |
Jun 1, 2026 |
PLCO-2047 |
| Scalable and Reproducible Deep Learning Strategies for Lung Cancer Screening Imaging |
Stefano Diciotti |
Alma Mater Studiorum - Department DEI |
NLST |
Jun 1, 2026 |
NLST-1514 |
| Deep Learning to Improve Screening of Interstitial Lung Diseases (NLST-1505 continued) |
Charles Hatt |
IMBIO, a 4D Medical Company |
NLST |
Jun 1, 2026 |
NLST-1506 |
| Heterogeneity of screening effects (Original Project: NLST-1098) |
Hormuzd Katki |
American Cancer Society |
NLST |
May 29, 2026 |
NLST-1509 |
